Nishanth Thalambedu

Assistant Professor

UAMS

Also affiliated: Thomas Jefferson University (2020–2021); Thomas Jefferson University Hospital (2020–2023); University of Arkansas Medical Center (2022–2026); Abington Memorial Hospital (2019–2023)

Internal Medicine, College of Medicine

9 h-index 67 pubs 260 cited

Research Areas

Biomedical Subjects

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Nishanth Thalambedu's research focuses on clinical outcomes and treatment strategies for hematologic malignancies and cardiovascular conditions. He has investigated the clinical outcomes of patients with relapsed refractory multiple myeloma undergoing BCMA-directed CAR-T therapy and the feasibility of outpatient stem cell transplantation for multiple myeloma, identifying predictive risk factors for hospital admission. His work also includes studying corneal toxicity associated with belantamab mafodotin and examining trends and outcomes of TAVI and SAVR in cancer and noncancer patients. Additionally, Thalambedu has contributed to research on the predictability of CRP and D-Dimer levels for in-hospital outcomes and mortality in COVID-19 patients, and has conducted a meta-analysis comparing valve-in-valve TAVI and redo-SAVR in patients with degenerated bioprosthetic aortic valves. His scholarship metrics include an h-index of 8, with 67 total publications and 259 total citations.

Metrics

h-index: 9
Publications: 67
Citations: 260

Positions

Assistant Professor publications 2022–2026

University of Arkansas for Medical Sciences Internal Medicine, College of Medicine Institutional directory

Selected Publications

Immunotherapy role in bladder cancer treatment: a review of literature (2026)

Frontiers in Oncology DOI OpenAlex
Real-world analysis of CRS and ICANS following tarlatamab and its association with survival in patients with SCLC. (2026)

Journal of Clinical Oncology DOI OpenAlex
Real-World Survival Outcomes of CAR-T and Bispecific T-cell Engagers in Patients with relapsed/refractory DLBCL (2026)

Transplantation and Cellular Therapy DOI OpenAlex
Impact of the CAR-T era on survival in diffuse large B-cell lymphoma: A u.S. population-based cohort study (2025)

Blood DOI OpenAlex
Editorial: Progressive role of artificial intelligence in treatment decision-making in the field of medical oncology (2025)

Frontiers in Medicine DOI OpenAlex
Navigating Hyperhemolysis in Sickle Cell Disease: Insights from Literature (2025)

Diagnostics 8 citations DOI OpenAlex
Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions (2025)

Frontiers in Medicine 15 citations DOI OpenAlex
Role of proliferation-related genes as predictive factors for adjuvant therapy in colon cancer. (2025)

Journal of Clinical Oncology DOI OpenAlex
Abstract 1124: Mining the Kras-p53 mutational interface for synthetic lethality (SL) in pancreatic adenocarcinoma (PA) (2025)

Cancer Research DOI OpenAlex
Unveiling Myelodysplastic Syndromes: Exploring Pathogenic Mechanisms and Therapeutic Advances (2025)

Cancers 5 citations DOI OpenAlex
Eculizumab for Hyperhemolysis in Sickle Cell Disease: Key Insights From a Challenging Case (2024)

Annals of Internal Medicine Clinical Cases DOI OpenAlex
Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
HL-697 Demographics and Survival Outcomes of Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): A Retrospective Analysis of SEER Database (2024)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Abstract B009: Exploring the putative Kras-p53 mutational interface for vulnerability (2024)

Molecular Cancer Therapeutics DOI OpenAlex
Demographics and survival outcomes of stage IV male breast cancer: A retrospective analysis of SEER database. (2024)

Journal of Clinical Oncology DOI OpenAlex